Equities Analysts Issue Forecasts for Corcept Therapeutics Incorporated’s FY2025 Earnings (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at HC Wainwright dropped their FY2025 earnings estimates for shares of Corcept Therapeutics in a report issued on Thursday, May 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $1.40 per share for the year, down from their previous estimate of $1.44. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.97 per share.

Other equities analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 3rd. Truist Financial boosted their price objective on Corcept Therapeutics from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Corcept Therapeutics has an average rating of “Buy” and an average price target of $40.10.

Corcept Therapeutics Price Performance

NASDAQ:CORT opened at $24.48 on Monday. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $34.28. The business has a 50 day simple moving average of $23.99 and a 200 day simple moving average of $25.13. The firm has a market capitalization of $2.55 billion, a P/E ratio of 23.09 and a beta of 0.50.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.04. The company had revenue of $146.80 million during the quarter, compared to the consensus estimate of $141.19 million. Corcept Therapeutics had a return on equity of 24.19% and a net margin of 22.38%. Corcept Therapeutics’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.14 earnings per share.

Insider Activity

In other Corcept Therapeutics news, insider Sean Maduck sold 27,068 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.97, for a total value of $702,955.96. Following the completion of the sale, the insider now directly owns 74,455 shares in the company, valued at $1,933,596.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Sean Maduck sold 27,068 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.97, for a total value of $702,955.96. Following the sale, the insider now owns 74,455 shares of the company’s stock, valued at approximately $1,933,596.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $23.59, for a total value of $51,898.00. The disclosure for this sale can be found here. Insiders sold 92,413 shares of company stock worth $2,352,176 over the last three months. Corporate insiders own 20.50% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC acquired a new position in Corcept Therapeutics in the third quarter worth approximately $202,000. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Corcept Therapeutics during the third quarter worth $4,726,000. New York State Teachers Retirement System lifted its holdings in shares of Corcept Therapeutics by 2.7% during the third quarter. New York State Teachers Retirement System now owns 140,461 shares of the biotechnology company’s stock valued at $3,827,000 after purchasing an additional 3,734 shares during the last quarter. Strs Ohio acquired a new position in shares of Corcept Therapeutics in the 3rd quarter valued at $54,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Corcept Therapeutics by 351.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 83,697 shares of the biotechnology company’s stock worth $2,280,000 after purchasing an additional 65,148 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.